Skip to content

Influence of Age on the Choice of Treatment and Prognosis in Patients With Resectable Gastric Cancer

Influence of Age on the Choice of Treatment and Prognosis in Patients With Resectable Gastric Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07403916
Enrollment
90
Registered
2026-02-11
Start date
2020-01-10
Completion date
2026-06-01
Last updated
2026-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer (GC), Molecular Analysis, Next-generation Sequencing

Keywords

Gastric cancer surgery, Next-generation sequencing, Gastric cancer treatment

Brief summary

Next-generation sequencing (NGS) and biomarkers play a key role in the diagnosis and personalized therapy of gastric cancer. These technologies provide a deep understanding of the molecular basis of the disease. NGS allows simultaneous analysis of multiple genes, identifying mutations and changes in their expression. In case of stomach cancer, this makes it possible to identify specific mutations to determine prognosis and treatment choice, study the genomic profiles of patients to find targets for targeted and immunotherapy. The use of NGS and biomarkers allows the development of individualized treatment regimens, increasing effectiveness and reducing side effects. Biomarker analysis also helps to track the progression of the disease and identify patients at high risk of relapse. The study of molecular genetic markers in tumor tissues, as well as the influence of genetic and age-related factors, is an important scientific and clinical task. Solving this problem will create a personalized approach to patient management. This work examines the influence of age on the choice of treatment tactics and prognosis in patients with resectable gastric cancer. The main focus is on the analysis of surgical, chemotherapeutic, topographic, pathomorphological, and molecular genetic correlations in various age groups.

Detailed description

Gastric cancer remains one of the most important malignant tumors with significant geographical and regional differences in prevalence. Despite the decrease in the incidence of gastric cancer in advanced economies, this pathology still ranks fifth among patients with malignant neoplasms. As for cancer mortality rates, stomach cancer ranks third. Stomach cancer continues to be one of the most significant oncological diseases in the world, ranking fifth in terms of prevalence according to global statistics from GLOBOCAN 2022. Modern medicine uses diagnostic technology - Next-generation sequencing (NGS), and biomarkers play an important role in the diagnosis, prognosis, and treatment of stomach cancer. These technologies provide a deep understanding of the molecular mechanisms underlying the disease and open up new possibilities for personalized therapy. NGS allows simultaneous analysis of multiple genes and detection of mutations, changes in gene expression and other genetic features. In the context of stomach cancer, next-generation sequencing allows for identification of mutations: Detection of specific mutations associated with stomach cancer can help determine prognosis and select appropriate treatment, study of the genomic profiles of patients: To identify potential targets for therapy, including immune and targeted drugs. With the help of NGS and biomarkers, doctors can develop individualized treatment regimens for different age groups, which increases the effectiveness of therapy and reduces side effects. Biomarker analysis allows you to track the progression of cancer and identify patients with a high risk of recurrence. The study and determination of molecular genetic markers in tumor tissues, as well as the analysis of genetic and age-related factors influencing the development of gastric cancer, is an important scientific and clinical task. Solving this problem may allow us to develop a personalized approach to patient management. This scientific paper will address the issue of the influence of age on the choice of treatment tactics and prognosis in patients with resectable gastric cancer. The main focus is on surgical, chemotherapeutic, topographic, pathomorphological, and molecular genetic correlations of various age groups in resectable gastric cancer.

Interventions

Technology for determining the sequence of DNA to study genetic variation associated with diseases or other biological phenomena

Sponsors

P. Herzen Moscow Oncology Research Institute
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with histologically confirmed diagnosis of gastric cancer * The resectable stage of the disease (I-III) * Availability of complete clinical data, including age, gender, stage of the disease, concomitant diseases, treatment tactics and outcomes * Indicated radical surgical intervention both at the first stage and after neoadjuvant chemotherapy * Localization of the tumor: Type II-III cardioesophageal junction according to Siewert, upper, middle and lower third of the body, angle of the stomach or antrum (U,M,L-level according to the Japanese classification)

Exclusion criteria

* The presence of metastases in distant organs at the time of diagnosis * Primary-multiple tumors * Diagnostic and palliative surgery * Incomplete clinical data * Pregnancy

Design outcomes

Primary

MeasureTime frame
Overall survival3 months

Secondary

MeasureTime frame
Mutational burden and genomic instability features assessed by NGS3 months
Spectrum of somatic mutations identified by NGS3 months
Disease free survival3 months

Countries

Russia

Contacts

STUDY_DIRECTORAndrey Ryabov, MD, PhD

P.Herzen Moscow Oncological Research Institute

PRINCIPAL_INVESTIGATORVakhtang Begiashvili, PhD student

P.Herzen Moscow Oncological Research Institute

PRINCIPAL_INVESTIGATORVladimir Khomyakov, MD, PhD

P.Herzen Moscow Oncological Research Institute

PRINCIPAL_INVESTIGATORNadezhda Volchenko, MD, PhD

P.Herzen Moscow Oncological Research Institute

PRINCIPAL_INVESTIGATORShatalov Peter, PhD

P.Herzen Moscow Oncological Research Institute

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026